170 related articles for article (PubMed ID: 8559495)
1. Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy.
Caravaca F; López-Minguez JR; Arrobas M; Cubero J; Pizarro JL; Cid MC; Sanchez-Casado E; Miranda MP
Nephrol Dial Transplant; 1995; 10(9):1720-4. PubMed ID: 8559495
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group).
Muirhead N; Laupacis A; Wong C
Nephrol Dial Transplant; 1992; 7(8):811-6. PubMed ID: 1325613
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
Henry DH; Abels RI
Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
[TBL] [Abstract][Full Text] [Related]
4. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients.
Cannella G; La Canna G; Sandrini M; Gaggiotti M; Nordio G; Movilli E; Maiorca R
Clin Nephrol; 1990 Dec; 34(6):272-8. PubMed ID: 2073771
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
6. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M
Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin.
Bárány P; Pettersson E; Konarski-Svensson JK
Nephrol Dial Transplant; 1993; 8(5):426-32. PubMed ID: 8393547
[TBL] [Abstract][Full Text] [Related]
8. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
9. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy.
Fjornes T; Wiedemann GJ; Sack K; Jelkmann W
Oncol Rep; 1998; 5(1):81-6. PubMed ID: 9458299
[TBL] [Abstract][Full Text] [Related]
10. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics.
Tagawa H; Nagano M; Saito H; Umezu M; Yamakado M
Clin Nephrol; 1991 Jan; 35(1):35-8. PubMed ID: 2007294
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment.
Baron F; Frère P; Fillet G; Beguin Y
Clin Cancer Res; 2003 Nov; 9(15):5566-72. PubMed ID: 14654537
[TBL] [Abstract][Full Text] [Related]
12. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
[TBL] [Abstract][Full Text] [Related]
13. The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.
Odabas AR; Cetinkaya R; Selcuk Y; Keles S; Bilen H
Panminerva Med; 2003 Mar; 45(1):59-62. PubMed ID: 12682621
[TBL] [Abstract][Full Text] [Related]
14. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
Lui SF; Law CB; Ting SM; Li P; Lai KN
Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
[TBL] [Abstract][Full Text] [Related]
15. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
[TBL] [Abstract][Full Text] [Related]
16. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 120(6):797-803. PubMed ID: 17391740
[TBL] [Abstract][Full Text] [Related]
17. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin deficiency and relative resistance cause anaemia in post-renal transplant recipients with normal renal function.
Nampoory MR; Johny KV; al-Hilali N; Seshadri MS; Kanagasabhapathy AS
Nephrol Dial Transplant; 1996 Jan; 11(1):177-81. PubMed ID: 8649630
[TBL] [Abstract][Full Text] [Related]
19. [Can anemia be corrected in hemodialysis patients with thalassaemia minor? ].
Di Iorio B; Guastaferro P; Gironda A; Marano V; Morrongiello L; Cillo N; Zito B; Nigro F; Frieri A; Rubino R; Bellizzi V
G Ital Nefrol; 2002; 19(5):552-9. PubMed ID: 12439845
[TBL] [Abstract][Full Text] [Related]
20. An assessment of cardiopulmonary bypass-induced changes in platelet function using whole blood and classical light transmission aggregometry: the results of a pilot study.
Velik-Salchner C; Maier S; Innerhofer P; Kolbitsch C; Streif W; Mittermayr M; Praxmarer M; Fries D
Anesth Analg; 2009 Jun; 108(6):1747-54. PubMed ID: 19448196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
